(Q33851127)

29 July 2017

1 reference

title

The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer (English)

1 reference

29 July 2017

Malkowicz SB

1

1 reference

29 July 2017

1 February 2000

1 reference

Urologic Clinics of North America

29 July 2017

1 reference

29 July 2017

27

1 reference

29 July 2017

1

1 reference

29 July 2017

63-73, ix

1 reference

Initial evaluation of the bladder tumor antigen test in superficial bladder cancer

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Human complement factor H: two factor H proteins are derived from alternatively spliced transcripts

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Evaluating serial cancer marker studies in patients at risk of recurrent disease

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Rapid detection of bladder cancer: a comparative study of point of care tests

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Basic principles of ROC analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Defining the ideal tumor marker for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Noninvasive detection of bladder cancer with the BTA stat test

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Comparison of screening methods in the detection of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Improved detection of recurrent bladder cancer using the Bard BTA stat Test

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's primer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970235-4

7 January 2021

10.1016/S0094-0143(05)70235-4

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10696246